Karl Schwartz, Artist advocate23h ago

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic #Pancreatic #Cancer

#news

https://finance.yahoo.com/sectors/healthcare/articles/daraxonrasib-demonstrates-unprecedented-overall-survival-120000437.html

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future...

Yahoo Finance
Kpop News HubFeb 5
NCT's Jisung Makes Big Donation Towards Pancreatic Cancer Research #Big #Cancer #Donation #Jisung #NCTs #Pancreatic #Research
https://kpopnewshub.com/ncts-jisung-makes-big-donation-towards-pancreatic-cancer-research/?fsp_sid=10112
NCT's Jisung Makes Big Donation Towards Pancreatic Cancer Research - KpopNewsHub – Latest K-Pop News, Idols & Korean Entertainment

1 hour ago

Kpop News Hub
Knowledge ZoneJan 31

#KnowledgeByte: #Pancreatic #Cancer is a leading cause of cancer-related mortality worldwide.

Recent research by Spanish Scientist Mariano Barbacid has yielded promising breakthroughs in laboratory settings and clinical trials.

https://knowledgezone.co.in/posts/Cure-for-pancreatic-cancer-in-sight-697d9e576d67746ca5d5d1be

Scientific FrontlineNov 12
Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the #oncogenic enzyme Pin1, a #protein that is overexpressed in many #tumors including #pancreatic cancer. They designed compounds that bind to Pin1 and destabilize its structure, causing its cellular degradation.
#Oncology #Cancer #sflorg
https://www.sflorg.com/2025/11/ongy11122501.html
Scientists move closer to better pancreatic cancer treatments

Collaboration between UC Riverside and City of Hope aims to eliminate cancer-causing proteins

Howard Smith MD, AMOct 31
New Weapon Against Breast Cancer. A new, supercharged form of immunotherapy for breast cancer has just been announced by UCLA oncologists. #immunotherapy #CARNKT #cancer #breast #triplenegative #ovarian #pancreatic #lung
https://www.instagram.com/p/DQdod3Mj3HW/
Howard G. Smith MD, AM on Instagram: "#deafness #children #congenital #otoferlin #dboto deafness, children, congenital, otoferlin, dboto ========================== FUTURE MED ========================== New Weapon Against Breast Cancer A new, supercharged form of immunotherapy for breast cancer has just been announced by UCLA oncologists in the Journal of Hematology & Oncology. The new approach involves the production of CAR-NKT cells, standing for chimeric antigen receptor-natural killer T cells, that have the superpower to attack not one but dozens of tumor cell surface antigens simultaneously. The cells target a protein mesothelin, which cancers need to rapidly grow and spread. Many current immunotherapies only target a single receptor. Triple negative breast cancers lack many of these common receptors making them difficult to treat successfully. This CAR-NKT therapy attacks so many receptors it could prove effective for those with these triple negative cancers. Even better, the CAR-NKT cells can be mass-produced from donated stem cells and stored for immediate use on demand. Very promising is the fact that the CAR-NKT cells target, mesothelin, is not only found on breast cancers but also on the surfaces of ovarian, pancreatic, and lung cancer cells. So far, these CAR-NKT cells have only been tested in the laboratory on tissue cultured breast cancer cells harvested from patient swith advanced disease. Clinical trials are in the planning stages, and hopefully, this super-immunotherapy will be available to save patients with a variety of difficult-to-treat cancers…..someday soon. https://www.news-medical.net/news/20251022/New-type-of-immunotherapy-could-change-the-treatment-plan-for-triple-negative-breast-cancer.aspx https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01736-9 #immunotherapy #CAR-NKT #cancer #breast #triplenegative #ovarian #pancreatic #lung"

UCLA scientists have made a significant breakthrough in the fight against triple-negative breast cancer with the discovery of a super-immunotherapy. This revolutionary treatment uses CAR-NKT cells to attack multiple tumor cell antigens, offering new hope for patients with this aggressive form of breast cancer. The CAR-NKT cells can be mass-produced from donated stem cells and stored for immediate use, making it a promising treatment option for those with triple-negative breast cancer.

Instagram
Howard Smith MD, AMOct 5, 2025
Pancreatic Cancer Drug. University of Cincinnati oncologists have developed a drug that stops pancreatic cancer from suppressing the anti-tumor immunity that threatens to eradicate it. #pancreatic #cancer #immunotherapy #hsp70 #sapCDOPG
https://www.instagram.com/p/DPa20mdDoub/
Howard G. Smith MD, AM on Instagram: "Pancreatic Cancer Drug University of Cincinnati oncologists have developed a drug that stops pancreatic cancer from suppressing the anti-tumor immunity that threatens to eradicate it. Using a pre-clinical mouse pancreatic cancer model, the researchers pinpointed that the protein Hsp70 is produced by the cancer cells to defuse the anti-cancer immune response. Their next step was to find an antidote Hp70. That they did by developing the rescue agent SapC-DOPG. This drug adheres to pancreatic cancer cells, inhibits Hsp70, and destroys the tumor’s shield against killer T lymphocytes. The next step is to bring this rescue compound and others like it into the clinic for an array of trials. Hopefully, they will confirm the effectiveness of this concept and join the fight against this dread disease…..someday soon. #pancreatic #cancer #immunotherapy #hsp70 #sapCDOPG"

0 likes, 0 comments - drhowardsmithreports on October 5, 2025: "Pancreatic Cancer Drug University of Cincinnati oncologists have developed a drug that stops pancreatic cancer from suppressing the anti-tumor immunity that threatens to eradicate it. Using a pre-clinical mouse pancreatic cancer model, the researchers pinpointed that the protein Hsp70 is produced by the cancer cells to defuse the anti-cancer immune response. Their next step was to find an antidote Hp70. That they did by developing the rescue agent SapC-DOPG. This drug adheres to pancreatic cancer cells, inhibits Hsp70, and destroys the tumor’s shield against killer T lymphocytes. The next step is to bring this rescue compound and others like it into the clinic for an array of trials. Hopefully, they will confirm the effectiveness of this concept and join the fight against this dread disease…..someday soon. #pancreatic #cancer #immunotherapy #hsp70 #sapCDOPG".

Instagram
Scientific FrontlineSep 24, 2025
A Cornell-led study has revealed how a deadly form of #pancreatic #cancer enters the bloodstream, solving a long-standing mystery of how the disease spreads and identifying a promising target for therapy.
#Biomedical #Biomolecular #sflorg
https://www.sflorg.com/2025/09/bmed09242501.html
Key driver of pancreatic cancer spread identified

In other words, ALK7 gives pancreatic cancer cells both the engine to move and the tools to invade

Howard Smith MD, AMAug 26, 2025
A Vaccine Against Pancreatic Cancer. An already FDA-approved cancer vaccine was spectacularly effective in controlling pancreatic cancers that carry the KRAS markers. #cancer #pancreatic #vaccine #ELI002 #elicio #iommunotherapy
https://www.instagram.com/p/DN0-HNvXPcP/
Howard G. Smith MD, AM on Instagram: "A Vaccine Against Pancreatic Cancer An already FDA-approved cancer vaccine was spectacularly effective in controlling pancreatic cancers that carry the KRAS markers. A multi-center phase 1 study, helmed by oncologists at New York’s Sloan Kettering and Texas’ MD Anderson, studied the vaccine labeled ELI-002 developed by Boston’s Elicio Therapeutics. The results demonstrated that the vaccine can trigger a vigorous killer T cell response to this KRAS marker carried by 88% of pancreatic cancers. They also showed that 65% of patients who mounted this T cell response to the vaccine enjoyed no radiographic progression of their cancers. Even more exciting, five of the sewpatients were free of tumor relapse without any subsequent therapy following the vaccine. When the study ended after nearly 20 months, these excellent responders were all alive without evidence of cancer recurrence. In contrast, the untreated controls developed cancer relapses in an average of 3 months and only survived an average of 15 months. Unlike most cancer vaccines that are custom produced for each patient’s tumor, ELI-002 can be mass produced making it readily available for administration and less expensive. A phase 2 trial of the vaccine is already in progress. Pancreatic cancer is one of the deadliest cancers, with only about 13% of patients surviving five years after diagnosis and recurrence rates as high as 80% within two years of surgery. Hopefully, this vaccine immunotherapy will help change those dismal statistics. https://www.nature.com/articles/s41591-025-03876-4 #cancer #pancreatic #vaccine #ELI002 #elicio #iommunotherapy"

0 likes, 0 comments - drhowardsmithreports on August 26, 2025: "A Vaccine Against Pancreatic Cancer An already FDA-approved cancer vaccine was spectacularly effective in controlling pancreatic cancers that carry the KRAS markers. A multi-center phase 1 study, helmed by oncologists at New York’s Sloan Kettering and Texas’ MD Anderson, studied the vaccine labeled ELI-002 developed by Boston’s Elicio Therapeutics. The results demonstrated that the vaccine can trigger a vigorous killer T cell response to this KRAS marker carried by 88% of pancreatic cancers. They also showed that 65% of patients who mounted this T cell response to the vaccine enjoyed no radiographic progression of their cancers. Even more exciting, five of the sewpatients were free of tumor relapse without any subsequent therapy following the vaccine. When the study ended after nearly 20 months, these excellent responders were all alive without evidence of cancer recurrence. In contrast, the untreated controls developed cancer relapses in an average of 3 months and only survived an average of 15 months. Unlike most cancer vaccines that are custom produced for each patient’s tumor, ELI-002 can be mass produced making it readily available for administration and less expensive. A phase 2 trial of the vaccine is already in progress. Pancreatic cancer is one of the deadliest cancers, with only about 13% of patients surviving five years after diagnosis and recurrence rates as high as 80% within two years of surgery. Hopefully, this vaccine immunotherapy will help change those dismal statistics. https://www.nature.com/articles/s41591-025-03876-4 #cancer #pancreatic #vaccine #ELI002 #elicio #iommunotherapy".

Instagram
beSpacificAug 14, 2025
Off-the-shelf #cancer #vaccine elicits strong #immune response in #patients with #pancreatic and #colorectal cancer. Final trial results show durable #Tcell responses and reduced #relapse in patients with pancreatic and colorectal cancer https://www.uclahealth.org/news/release/shelf-cancer-vaccine-elicits-strong-immune-response-patients #medicine #science #research #KRAS patients https://www.uclahealth.org/news/release/shelf-cancer-vaccine-elicits-strong-immune-response-patients #health #HealthResearch #healthcare
Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

The findings, published in Nature Medicine, show that the vaccine can trigger powerful and lasting immune responses and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations.

EssJay PURPLE PURPOSEApr 15, 2025
Via Pancan.org #KRAS Mutations and #Pancreatic Cancer. Understanding the biology of your particular tumor is key to finding the right treatment for pancreatic cancer. ⬇️ pancan.org/facing-pancr...

pancan.org/facing-pancrea...
Pancreatic Cancer Action Network – Research, Patient Support, Resources

We're the national organization providing support, resources, volunteer opportunities and hope for people fighting pancreatic cancer.

Pancreatic Cancer Action Network